Most MDR-TB Patients Cannot Access Latest Treatments Because Of High Prices, MSF Says

Thomson Reuters Foundation: New lifesaving drugs too expensive for most drug-resistant TB patients: MSF
“Only two percent of people with the most severe cases of drug-resistant tuberculosis (TB) have access to the latest life-saving drugs because of their high price, the medical charity Médecins Sans Frontières (MSF) said on Monday. The price of bedaquiline and delamanid, two new drugs for treating TB which are recommended by the World Health Organization, should be reduced, by up to 98 percent in the case of delamanid, to make them more accessible to 150,000 patients who need them, MSF said…” (Mis, 3/21).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.